Therapy Directory

Palbociclib clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Palbociclib as a study intervention. Browse Palbociclib recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 6:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

229

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Healthy, Hepatic Insufficiency
Interventions: Palbociclib 75 mg Capsule; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 2
States / cities: Orlando, Florida

Conditions: Sarcoma, Liposarcoma
Interventions: Palbociclib 200mg, Palbociclib 125mg; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy Volunteer
Interventions: Palbociclib, Rabeprazole; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Non-small Cell Lung Cancer
Interventions: PD0332991; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 2
States / cities: Gainesville, Florida • Tampa, Florida

Conditions: Neoplasms, Lymphoma, Non-Hodgkin
Interventions: PD-0332991; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2014
U.S. locations: 4
States / cities: Detroit, Michigan • New York, New York • Philadelphia, Pennsylvania

Conditions: Lymphoma, Mantle-Cell
Interventions: PD-0332991; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 6
States / cities: Boston, Massachusetts • New York, New York • Philadelphia, Pennsylvania

Conditions: Healthy
Interventions: Midazolam, PD-0332991; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: South Miami, Florida

Conditions: Healthy
Interventions: Palbociclib alone, Palbociclib + Rabeprazole; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: South Miami, Florida

Conditions: Healthy
Interventions: PD-0332991 alone, Tamoxifen 60 mg, Tamoxifen 20 mg, PD-0332991 combination; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Glioblastoma, Gliosarcoma, Anaplastic Astrocytoma
Interventions: PD 0332991 (pre-surgery), PD 0332991, Resection as clinical care; Drug · Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Healthy
Interventions: Palbociclib Alone, Palbociclib + Rabeprazole; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 3
States / cities: Miami, Florida • South Miami, Florida

Conditions: Multiple Myeloma
Interventions: Bortezomib, Dexamethasone, PD 0332991; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 16
States / cities: Chicago, Illinois • Kansas City, Kansas • Westwood, Kansas + 9 more

About this Palbociclib clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Palbociclib as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results: Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Palbociclib.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Palbociclib clinical trials

Filter and sort this therapy

Live official records

A Study To Describe The Effect Of Impaired Hepatic Function Of The Pharmacokinetics Of Palbociclib

PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma

Proton Pump Inhibitor (PPI, Rabeprazole) Effect On Tablet Formulation Of Palbociclib

Cyclin Dependent Kinase (CDK)4/6 Inhibitor, PD0332991 in Advanced Non-small Cell Lung Cancer NSCLC.

A Study Of Oral Palbociclib (PD-0332991), A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer

An Investigational Study Drug, Palbociclib (PD-0332991), Is Being Studied In Patients With Mantle Cell Lymphoma. Patients Must Have Received Prior Treatment(s) For Mantle Cell Lymphoma.

A Drug-Drug Interaction Study To Investigate The Potential For Multiple Doses Of Palbociclib (PD-0332991) To Alter The Pharmacokinetics Of Oral Midazolam In Adult Healthy Women of Non-Childbearing Potential.

Drug Interaction Study To Investigate The Potential Effect Of Proton Pump Inhibitor On The Pharmacokinetics Of Palbociclib (PD-0332991)

A Study To Determine If Coadministration Of Tamoxifen Alters The Extent Or Rate Of Palbociclib (PD-0332991) Absorption Or Elimination In Healthy Male Volunteers

A Study of PD 0332991 in Patients With Recurrent Rb Positive Glioblastoma

A Pilot Study To Investigate The Effect Of Concurrent Antacid Administration On The Bioavailability Of Six Experimental Formulations Of Palbociclib

An Investigational Drug, Palbociclib (PD-0332991), Is Being Studied In Combination With Velcade And Dexamethasone In Patients With Multiple Myeloma. Patients Must Have Received Prior Treatment For Multiple Myeloma.

About this Palbociclib clinical trials directory page